Please try another search
For the six months ended 30 June 2020, Aimmune Therapeutics Inc revenues increased from $0K to $575K. Net loss increased 33% to $155.7M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Employee-related costs increase of 83% to $36.3M (expense), General and Administrative - other increase of 50% to $36.5M (expense).
Period Ending: | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 |
---|---|---|---|---|
Total Revenue | 0 | 0.57 | 0 | 0 |
Gross Profit | -4.85 | 0.32 | ||
Operating Income | -65.99 | -85.28 | -66.99 | -64.6 |
Net Income | -69.24 | -86.43 | -66.9 | -64.45 |
Period Ending: | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 |
---|---|---|---|---|
Total Assets | 365.29 | 420.05 | 204.37 | 248.4 |
Total Liabilities | 185.43 | 185 | 100.34 | 95.71 |
Total Equity | 179.86 | 235.05 | 104.02 | 152.69 |
Period Ending: | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 |
---|---|---|---|---|
Period Length: | 6 Months | 3 Months | 12 Months | 9 Months |
Cash From Operating Activities | -126.92 | -71.81 | -195.41 | -142.84 |
Cash From Investing Activities | 26.11 | 4.86 | 111.9 | 67.41 |
Cash From Financing Activities | 287.48 | 285.48 | 55.88 | 44.77 |
Net Change in Cash | 186.68 | 218.54 | -27.63 | -30.67 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review